Arcoma AB (Sweden) Today
| ARCOMA Stock | SEK 10.70 0.15 1.38% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Arcoma AB is trading at 10.70 as of the 18th of January 2025, a 1.38 percent decrease since the beginning of the trading day. The stock's open price was 10.85. Arcoma AB has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscleskeleton, thoratic, pediatric, and traumaresus clinics. The company has 13.05 M outstanding shares. More on Arcoma AB
Moving together with Arcoma Stock
| 0.62 | XVIVO | Xvivo Perfusion AB | PairCorr |
| 0.67 | BICO | BICO Group AB | PairCorr |
| 0.88 | BACTI-B | Bactiguard Holding | PairCorr |
| 0.9 | ADDV-B | ADDvise Group B | PairCorr |
Moving against Arcoma Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Arcoma Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arcoma AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arcoma AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
Arcoma AB (ARCOMA) is traded on Stockholm Exchange in Sweden and employs 24 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 146.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arcoma AB's market, we take the total number of its shares issued and multiply it by Arcoma AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arcoma AB operates under Healthcare sector and is part of Medical Devices industry. The entity has 13.05 M outstanding shares.
Arcoma AB has accumulated about 811 K in cash with (1.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Check Arcoma AB Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Arcoma AB is kr146.18 Million. Arcoma AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Arcoma Ownership Details
Arcoma AB Risk Profiles
Although Arcoma AB's alpha and beta are two of the key measurements used to evaluate Arcoma AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.84 | |||
| Standard Deviation | 2.9 | |||
| Variance | 8.43 | |||
| Risk Adjusted Performance | (0.12) |
Arcoma Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Arcoma AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Arcoma AB Corporate Management
Elected by the shareholders, the Arcoma AB's board of directors comprises two types of representatives: Arcoma AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcoma. The board's role is to monitor Arcoma AB's management team and ensure that shareholders' interests are well served. Arcoma AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcoma AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frida Robbe | Marketing Mang | Profile | |
| Sanna Rydberg | Chief Officer | Profile | |
| Johan Dahlberg | Chief Officer | Profile | |
| Peter Reinli | Pres IMIX ADR Ltd | Profile | |
| Nicklas Johansson | Operations Manager | Profile |
Other Information on Investing in Arcoma Stock
Arcoma AB financial ratios help investors to determine whether Arcoma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arcoma with respect to the benefits of owning Arcoma AB security.